Home Healthcare Pharmaceuticals Dyslexia Treatment and Diagnosis Market

Dyslexia Treatment and Diagnosis Market Size, Share & Trends Analysis Report By Type (Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia, Others), By Drug Class (Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reputake Inhibitors, Others), By End-User (Psychiatric Institutions, Rehabilitation Centres, Home Care, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Debashree B | Format: | Report Code: SR3606DR | Pages: 110
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Dyslexia Treatment and Diagnosis Market, By Type 2022-2034 (USD MILLION/ Units)
    1. Phonological Dyslexia
    2. Surface Dyslexia
    3. Double Deficit Dyslexia
    4. Others
  2. Dyslexia Treatment and Diagnosis Market, By Drug Class 2022-2034 (USD MILLION/ Units)
    1. Antihistamines
    2. Central Nervous Stimulant
    3. Selective Norepinephrine Reputake Inhibitors
    4. Others
  3. Dyslexia Treatment and Diagnosis Market, By End-User 2022-2034 (USD MILLION/ Units)
    1. Psychiatric Institutions
    2. Rehabilitation Centres
    3. Home Care 
    4. Others
  4. Regional Dyslexia Treatment and Diagnosis Market
    1. North America
      1. North America Dyslexia Treatment and Diagnosis Market By Type 2022-2034 (USD MILLION/ Units)
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
      2. North America Dyslexia Treatment and Diagnosis Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Antihistamines
        2. Central Nervous Stimulant
        3. Selective Norepinephrine Reputake Inhibitors
        4. Others
      3. North America Dyslexia Treatment and Diagnosis Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Psychiatric Institutions
        2. Rehabilitation Centres
        3. Home Care 
        4. Others
      4. U.S.
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
        5. Antihistamines
        6. Central Nervous Stimulant
        7. Selective Norepinephrine Reputake Inhibitors
        8. Others
        9. Psychiatric Institutions
        10. Rehabilitation Centres
        11. Home Care 
        12. Others
      5. Canada
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
        5. Antihistamines
        6. Central Nervous Stimulant
        7. Selective Norepinephrine Reputake Inhibitors
        8. Others
        9. Psychiatric Institutions
        10. Rehabilitation Centres
        11. Home Care 
        12. Others
    2. Europe
      1. Europe Dyslexia Treatment and Diagnosis Market By Type 2022-2034 (USD MILLION/ Units)
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
      2. Europe Dyslexia Treatment and Diagnosis Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Antihistamines
        2. Central Nervous Stimulant
        3. Selective Norepinephrine Reputake Inhibitors
        4. Others
      3. Europe Dyslexia Treatment and Diagnosis Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Psychiatric Institutions
        2. Rehabilitation Centres
        3. Home Care 
        4. Others
      4. U.K.
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
        5. Antihistamines
        6. Central Nervous Stimulant
        7. Selective Norepinephrine Reputake Inhibitors
        8. Others
        9. Psychiatric Institutions
        10. Rehabilitation Centres
        11. Home Care 
        12. Others
      5. Germany
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
        5. Antihistamines
        6. Central Nervous Stimulant
        7. Selective Norepinephrine Reputake Inhibitors
        8. Others
        9. Psychiatric Institutions
        10. Rehabilitation Centres
        11. Home Care 
        12. Others
      6. France
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
        5. Antihistamines
        6. Central Nervous Stimulant
        7. Selective Norepinephrine Reputake Inhibitors
        8. Others
        9. Psychiatric Institutions
        10. Rehabilitation Centres
        11. Home Care 
        12. Others
      7. Spain
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
        5. Antihistamines
        6. Central Nervous Stimulant
        7. Selective Norepinephrine Reputake Inhibitors
        8. Others
        9. Psychiatric Institutions
        10. Rehabilitation Centres
        11. Home Care 
        12. Others
      8. Italy
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
        5. Antihistamines
        6. Central Nervous Stimulant
        7. Selective Norepinephrine Reputake Inhibitors
        8. Others
        9. Psychiatric Institutions
        10. Rehabilitation Centres
        11. Home Care 
        12. Others
      9. Russia
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
        5. Antihistamines
        6. Central Nervous Stimulant
        7. Selective Norepinephrine Reputake Inhibitors
        8. Others
        9. Psychiatric Institutions
        10. Rehabilitation Centres
        11. Home Care 
        12. Others
      10. Nordic
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
        5. Antihistamines
        6. Central Nervous Stimulant
        7. Selective Norepinephrine Reputake Inhibitors
        8. Others
        9. Psychiatric Institutions
        10. Rehabilitation Centres
        11. Home Care 
        12. Others
      11. Benelux
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
        5. Antihistamines
        6. Central Nervous Stimulant
        7. Selective Norepinephrine Reputake Inhibitors
        8. Others
        9. Psychiatric Institutions
        10. Rehabilitation Centres
        11. Home Care 
        12. Others
      12. Rest of Europe
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
        5. Antihistamines
        6. Central Nervous Stimulant
        7. Selective Norepinephrine Reputake Inhibitors
        8. Others
        9. Psychiatric Institutions
        10. Rehabilitation Centres
        11. Home Care 
        12. Others
    3. APAC
      1. APAC Dyslexia Treatment and Diagnosis Market By Type 2022-2034 (USD MILLION/ Units)
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
      2. APAC Dyslexia Treatment and Diagnosis Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Antihistamines
        2. Central Nervous Stimulant
        3. Selective Norepinephrine Reputake Inhibitors
        4. Others
      3. APAC Dyslexia Treatment and Diagnosis Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Psychiatric Institutions
        2. Rehabilitation Centres
        3. Home Care 
        4. Others
      4. China
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
        5. Antihistamines
        6. Central Nervous Stimulant
        7. Selective Norepinephrine Reputake Inhibitors
        8. Others
        9. Psychiatric Institutions
        10. Rehabilitation Centres
        11. Home Care 
        12. Others
      5. Korea
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
        5. Antihistamines
        6. Central Nervous Stimulant
        7. Selective Norepinephrine Reputake Inhibitors
        8. Others
        9. Psychiatric Institutions
        10. Rehabilitation Centres
        11. Home Care 
        12. Others
      6. Japan
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
        5. Antihistamines
        6. Central Nervous Stimulant
        7. Selective Norepinephrine Reputake Inhibitors
        8. Others
        9. Psychiatric Institutions
        10. Rehabilitation Centres
        11. Home Care 
        12. Others
      7. India
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
        5. Antihistamines
        6. Central Nervous Stimulant
        7. Selective Norepinephrine Reputake Inhibitors
        8. Others
        9. Psychiatric Institutions
        10. Rehabilitation Centres
        11. Home Care 
        12. Others
      8. Australia
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
        5. Antihistamines
        6. Central Nervous Stimulant
        7. Selective Norepinephrine Reputake Inhibitors
        8. Others
        9. Psychiatric Institutions
        10. Rehabilitation Centres
        11. Home Care 
        12. Others
      9. Taiwan
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
        5. Antihistamines
        6. Central Nervous Stimulant
        7. Selective Norepinephrine Reputake Inhibitors
        8. Others
        9. Psychiatric Institutions
        10. Rehabilitation Centres
        11. Home Care 
        12. Others
      10. South East Asia
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
        5. Antihistamines
        6. Central Nervous Stimulant
        7. Selective Norepinephrine Reputake Inhibitors
        8. Others
        9. Psychiatric Institutions
        10. Rehabilitation Centres
        11. Home Care 
        12. Others
      11. Rest of Asia-Pacific
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
        5. Antihistamines
        6. Central Nervous Stimulant
        7. Selective Norepinephrine Reputake Inhibitors
        8. Others
        9. Psychiatric Institutions
        10. Rehabilitation Centres
        11. Home Care 
        12. Others
    4. Middle East and Africa
      1. Middle East and Africa Dyslexia Treatment and Diagnosis Market By Type 2022-2034 (USD MILLION/ Units)
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
      2. Middle East and Africa Dyslexia Treatment and Diagnosis Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Antihistamines
        2. Central Nervous Stimulant
        3. Selective Norepinephrine Reputake Inhibitors
        4. Others
      3. Middle East and Africa Dyslexia Treatment and Diagnosis Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Psychiatric Institutions
        2. Rehabilitation Centres
        3. Home Care 
        4. Others
      4. UAE
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
        5. Antihistamines
        6. Central Nervous Stimulant
        7. Selective Norepinephrine Reputake Inhibitors
        8. Others
        9. Psychiatric Institutions
        10. Rehabilitation Centres
        11. Home Care 
        12. Others
      5. Turkey
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
        5. Antihistamines
        6. Central Nervous Stimulant
        7. Selective Norepinephrine Reputake Inhibitors
        8. Others
        9. Psychiatric Institutions
        10. Rehabilitation Centres
        11. Home Care 
        12. Others
      6. Saudi Arabia
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
        5. Antihistamines
        6. Central Nervous Stimulant
        7. Selective Norepinephrine Reputake Inhibitors
        8. Others
        9. Psychiatric Institutions
        10. Rehabilitation Centres
        11. Home Care 
        12. Others
      7. South Africa
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
        5. Antihistamines
        6. Central Nervous Stimulant
        7. Selective Norepinephrine Reputake Inhibitors
        8. Others
        9. Psychiatric Institutions
        10. Rehabilitation Centres
        11. Home Care 
        12. Others
      8. Egypt
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
        5. Antihistamines
        6. Central Nervous Stimulant
        7. Selective Norepinephrine Reputake Inhibitors
        8. Others
        9. Psychiatric Institutions
        10. Rehabilitation Centres
        11. Home Care 
        12. Others
      9. Nigeria
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
        5. Antihistamines
        6. Central Nervous Stimulant
        7. Selective Norepinephrine Reputake Inhibitors
        8. Others
        9. Psychiatric Institutions
        10. Rehabilitation Centres
        11. Home Care 
        12. Others
      10. Rest of MEA
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
        5. Antihistamines
        6. Central Nervous Stimulant
        7. Selective Norepinephrine Reputake Inhibitors
        8. Others
        9. Psychiatric Institutions
        10. Rehabilitation Centres
        11. Home Care 
        12. Others
    5. LATAM
      1. LATAM Dyslexia Treatment and Diagnosis Market By Type 2022-2034 (USD MILLION/ Units)
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
      2. LATAM Dyslexia Treatment and Diagnosis Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Antihistamines
        2. Central Nervous Stimulant
        3. Selective Norepinephrine Reputake Inhibitors
        4. Others
      3. LATAM Dyslexia Treatment and Diagnosis Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Psychiatric Institutions
        2. Rehabilitation Centres
        3. Home Care 
        4. Others
      4. Brazil
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
        5. Antihistamines
        6. Central Nervous Stimulant
        7. Selective Norepinephrine Reputake Inhibitors
        8. Others
        9. Psychiatric Institutions
        10. Rehabilitation Centres
        11. Home Care 
        12. Others
      5. Mexico
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
        5. Antihistamines
        6. Central Nervous Stimulant
        7. Selective Norepinephrine Reputake Inhibitors
        8. Others
        9. Psychiatric Institutions
        10. Rehabilitation Centres
        11. Home Care 
        12. Others
      6. Argentina
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
        5. Antihistamines
        6. Central Nervous Stimulant
        7. Selective Norepinephrine Reputake Inhibitors
        8. Others
        9. Psychiatric Institutions
        10. Rehabilitation Centres
        11. Home Care 
        12. Others
      7. Chile
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
        5. Antihistamines
        6. Central Nervous Stimulant
        7. Selective Norepinephrine Reputake Inhibitors
        8. Others
        9. Psychiatric Institutions
        10. Rehabilitation Centres
        11. Home Care 
        12. Others
      8. Colombia
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
        5. Antihistamines
        6. Central Nervous Stimulant
        7. Selective Norepinephrine Reputake Inhibitors
        8. Others
        9. Psychiatric Institutions
        10. Rehabilitation Centres
        11. Home Care 
        12. Others
      9. Rest of LATAM
        1. Phonological Dyslexia
        2. Surface Dyslexia
        3. Double Deficit Dyslexia
        4. Others
        5. Antihistamines
        6. Central Nervous Stimulant
        7. Selective Norepinephrine Reputake Inhibitors
        8. Others
        9. Psychiatric Institutions
        10. Rehabilitation Centres
        11. Home Care 
        12. Others
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.